[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","hnxp01bdsockjpdici13zyllz","revision",2,"title","Helus Pharma 提交 6-K 文件并附 11 月 3 日新闻稿","originalTitle","6-K - Helus Pharma Inc. (0001833141) (Filer)","summary","Helus Pharma Inc. 于 11 月 3 日签署并提交 Form 6-K，作为外国私人发行人依《证券交易法》相关规则提交的报告。文件附有一份日期为 11 月 3 日的新闻稿，未提供其内容。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-11-03T16:23:32.000Z","discoveredAt","2026-11-04T06:10:18.748Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",16,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fwDH0DALASA4",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c372ba89-2774-4a04-b960-1144f25c3622","Helus Pharma提交6-K文件",{"_72":73,"_15":74},"zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2026.

Commission File Number: 001-40673

Helus Pharma Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	HELUS PHARMA INC.
	(Registrant)

Date: November 3, 2026	By:	/s/ Greg Cavers
	Name:	Greg Cavers
	Title:	Chief Financial Officer

EXHIBIT INDEX

\n \n \n \n \n

99.1	News Release dated November 3, 2026

","zhKind","complete","HELP","公司与财报","aihot","/items/hnxp01bdsockjpdici13zyllz","https://www.sec.gov/Archives/edgar/data/1833141/000106299326005696/0001062993-26-005696-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794960000&sig=44baa70fbeef50e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794960000&sig=a4957e0f65b84b31 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794960000&sig=c50e8e83f0dcfb02 96w","changelogVersion","2026-10-01T08:00"]